Sulanda (surufatinib) / Hutchmed - LARVOL DELTA

Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma (ESMO 2026) - No abstract available

Clinical • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study. (PubMed, Signal Transduct Target Ther) - P1/2 | "Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited first-line treatments. In the NASCA group, enrichment of CD8+ and CD8+PD-1+ cells, a high baseline M1/M2 macrophage ratio, and a reduction in CA19-9 levels at weeks 6 and 12 were associated with improved PFS compared to patients without these features. The NASCA regimen showed promising efficacy with tolerable safety relative to nab-paclitaxel and gemcitabine for locally advanced or metastatic PDAC."

Clinical • Journal • P1/2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CA 19-9 • CD8 • PD-1

Clinical activity of chidamide-containing regimens after prior PD-1-based therapy in two patients with microsatellite-stable metastatic colorectal cancer: a case series and narrative review. (PubMed, Front Oncol) - "Case 1: A 60-year-old woman with BRAF V600E-mutant, right-sided, MSS mCRC received third-line surufatinib plus camrelizumab, with a best response of stable disease (SD) and a progression-free survival (PFS) of 5 months...Case 2: A 43-year-old man with recurrent RAS/BRAF wild-type MSS mCRC received fifth-line surufatinib plus sintilimab (PR, PFS 8.5 months) and, after progression, seventh-line chidamide plus sintilimab plus bevacizumab (SD, PFS 5.5 months)...As descriptive observations, these findings are hypothesis-generating only and are insufficient to demonstrate reversal of immunotherapy resistance or survival benefit. Prospective biomarker-driven studies are warranted to evaluate epigenetic-immunotherapy combinations in this subgroup."

IO biomarker • Journal • Colorectal Cancer • Gene Therapies • Oncology • Solid Tumor • BRAF

Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med) - P2 | "Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699)."

IO biomarker • Journal • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2 • PD-L1

Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Updates on Systemic Treatments for Advanced Pancreatic Neuroendocrine Neoplasm (IASGO 2026) - "Everolimus and sunitinib are established options for progressive disease...Alkylator-based chemotherapy, including streptozotocin/5-FU andcapecitabine/temozolomide, is preferred when substantial tumor shrinkage is required...NETTER-2 established 177Lu-DOTATATE plus octreotide as an important first-line option for newlydiagnosed, SSTR-positive G2/G3 gastroenteropancreatic NETs with a Ki-67 index of 10–55%.Cabozantinib significantly prolonged PFS in previously treated PanNETs in the CABINET trial.Surufatinib is approved in China, while belzutifan is indicated specifically for VHL-associated pNETsnot requiring immediate surgery. For PanNECs, platinum plus etoposide remains the frontline standard, whereas no universallyaccepted salvage regimen exists. Emerging approaches include targeted alpha therapy and DLL3-directed bispecific T-cell engagers, although their roles in PanNENs remain investigational. Futuretreatment will increasingly rely on integrated molecular profiling,..."

Metastases • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Carcinoma • Neuroendocrine Neoplasm • Neuroendocrine Tumor • Solid Tumor • ATRX • DAXX • DLL3 • SSTR • TP53

ZSPAC-22: Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

New P2 trial • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial. (ASCO 2026) - P1/2 | "Funded by HUTCHMED, ALPHAMAB Clinical Trial Registration Number: NCT05832892 Background: In China, gemcitabine (G) and nab-paclitaxel (nP) remain the standard first-line (1L) therapy for patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC). S plus K and GnP demonstrated consistently encouraging efficacy and manageable safety in 1L treatment of advanced PDAC. Early and sharp decline in CA199 may predict more favorable survival benefit. Analyses in genetic profile and its impact on clinical outcome will be carried out in future, and investigations in larger population are warranted."

Biomarker • Clinical • IO biomarker • Metastases • P1/2 data • Cardiovascular • Hematological Disorders • Hypertension • Neutropenia • Oncology • Pancreatic Ductal Adenocarcinoma • Thrombocytopenia • CA 19-9

Surufatinib Combined with Toripalimab and Nab-paclitaxel/gemcitabine Chemotherapy as First-Line Treatment for Advanced Pancreatobiliary-Type Ampullary Carcinoma: A Prospective Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ampulla of Vater Carcinoma • Oncology

Surufatinib Plus Chemotherapy Versus Surufatinib in Patients With Thoracic Neuroendocrine Tumor: A Randomized, Phase II Study (IASLC-WCLC 2026) - P2 | "Eligible participants aged 18 years or older, with an ECOG PS of 0-1, no prior systemic therapy, and histologically or cytologically confirmed stage IIIb-IV pulmonary, thymic, or mediastinal NETs will be randomized to the Surufatinib combination group [Surufatinib (250 mg, qd, po) plus either EC regimen (etoposide 100 mg/m2, iv, days 1-3; carboplatin AUC=5, iv, day 1; q3w, for 4-6 cycles) or CAPTEM regimen (capecitabine 750 mg/m2, bid, po, days 1-14; temozolomide 150-200 mg/m2, qd, po, days 10-14; q4w, for 4 cycles)] or to the Surufatinib monotherapy group [Surufatinib (300 mg qd, po)]. This study is ongoing at five clinical centers in China. As of March 31, 2026, 4 of the planned 96 patients had been enrolled: 2 in the surufatinib plus chemotherapy group and 2 in the surufatinib monotherapy group."

Clinical • P2 data • Neuroendocrine Tumor • Oncology • Solid Tumor • CSF1R • FGFR1 • FLT1

Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study. (PubMed, Int J Cancer) - P2 | "Serious adverse events occurred in 45.2% of patients. These findings suggest that surufatinib, IBI310, and sintilimab may offer clinical benefit with manageable toxicity in patients with advanced HG-NENs."

Journal • P2 data • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor

Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial (ESMO 2026) - No abstract available

Clinical • Metastases • P1/2 data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

A Phase Ib/II Study of Radiotherapy (RT) Combined with Surufatinib (SUR) and Sintilimab (SIN) for Localized High-Risk Limb and Trunk Soft Tissue Sarcomas (STS): A Prospective Single-Center Trial (ESMO 2026) - No abstract available

Clinical • P1/2 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study (AACR 2026) - P2 | "Induction therapy with 6 weeks of AG followed by sequential surufatinib plus AG demonstrated promising efficacy with a manageable safety profile as first-line treatment for mPDAC. This therapeutic strategy may be particularly beneficial for patients without metastatic organs or those who achieve a ≥90% reduction in CA19-9 during treatment."

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma • CA 19-9 • CSF1R • FGFR1 • FLT1

Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma. (ASCO 2026) - P4 | "Pts received surufatinib (250mg, orally, once daily), ICI (Zimberelimab or Toripalimab, 240mg, intravenous infusion, d1, q3w), and chemotherapy (gemcitabine 1000mg/m2 intravenous infusion, 30min, d1, d8, q3w; cisplatin 25mg/m2 intravenous infusion, 2h, d1, d8, q3w) until disease progression, death, surgery, intolerable toxicity, or withdrawal of consent. Surufatinib plus gemcitabine and cisplatin combined with immune checkpoint inhibitor, the chemotherapy regimen as the standard treatment in combination with targeted and immunotherapy showed preliminary anti-tumor activity and manageable toxicity for the 1L treatment of ICC, providing an additional treatment option for pts with ICC. This study has been completed and the paper has been prepared for submission, the final results details will be published after the conference."

Checkpoint inhibition • Metastases • Biliary Cancer • Cholangiocarcinoma • Hypertension • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • CSF1R • FGFR1 • FLT1

Surufatinib Combined With First-Line Serplulimab and Chemotherapy for ES-SCLC: A Prospective Single-Arm Trial (IASLC-WCLC 2026) - "The BEAT-SC trial showed no survival benefit with bevacizumab, whereas the ETER701 trial of anlotinib reported improved efficacy but also significantly increased toxicity, which limited sustained maintenance dosing and attenuated long-term benefit...Patients received surufatinib 200 mg orally once daily, serplulimab 300 mg intravenously on day 1, etoposide 100 mg/m2 intravenously on days 1-3, with either carboplatin AUC 5 or cisplatin 75 mg/m2 on day 1 of each 21-day cycle, followed by maintenance therapy with surufatinib and serplulimab...These preliminary results warrant further validation in larger cohorts with long-term follow-up. This study is still ongoing."

Clinical • Lung Cancer • Small Cell Lung Cancer • Solid Tumor • CSF1R

Six Weeks of Induction Gemcitabine Plus Nab Paclitaxel (AG) Followed by Sequential Surufatinib Plus AG or AG alone as First Line Therapy for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): A Single Center, Two Cohort, Phase II Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

Surufatinib Plus Serplulimab, Etoposide, and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Updated Results from a Single-Arm, Phase Ia/Ib Trial (ESMO 2026) - No abstract available

Clinical • P1 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study (ESMO 2026) - No abstract available

Clinical • P2 data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology

Matching-Adjusted Indirect Comparison of Surufatinib versus High-Dose OCT-LAR in Patients with Advanced GEP-NETs Who Progressed on Prior SSA Therapy (ESMO 2026) - No abstract available

Clinical • Metastases • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology

Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors (ESMO 2026) - No abstract available

Clinical • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

Efficacy and Safety of Surufatinib(Suru) in Combination with CAPTEM in Advanced G2/G3 Neuroendocrine Tumors: Results from a Single-Arm, Phase II Trial (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P2 data • Neuroendocrine Tumor • Oncology • Solid Tumor

Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Yefeng

New trial • Real-world evidence • Neuroendocrine Tumor • Oncology • Solid Tumor

Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study. (PubMed, Ther Adv Med Oncol) - "Surufatinib was a promising therapeutic option for G3 NETs. Prospective, larger-scale cohorts are warranted to confirm the efficacy and address the predictive markers for better patient selection."

Clinical • Journal • Real-world evidence • Neuroendocrine Tumor • Oncology • Solid Tumor

Global sales growth driven by China rebound and FRUZAQLA geographical expansion (The Manila Times) - "In-market sales from key China commercial products up over 40% compared to the first half of 2025. ELUNATE (fruquintinib in China) up 41% to $60.8 million as it expanded reimbursement coverage for endometrial cancer and was approved for kidney cancer. SULANDA up 45% to $18.4 million, boosted by upgraded recommendation in Chinese Society of Clinical Oncology guidelines for neuroendocrine tumors; In-market sales of FRUZAQLA (fruquintinib ex-China) ex-US up ~70% to $68.9 million during first half of 2026, alongside steady US sales, driven by the need for novel non-chemo treatment options in mCRC and ongoing positive experiences of oncologists in third line setting; Profitability maintained amid higher R&D investment, with net income attributable to HUTCHMED at $15.9 million..."

pMMR • Sales • Colorectal Cancer • Endometrial Cancer • Kidney Cancer • Neuroendocrine Tumor • Renal Cell Carcinoma